Purpose: Dihydropyrimidine dehydrogenase (DPD), the initial rate-limiting enzyme in the degradation of 5-fluorouracil (5-FU), is known to be a principal factor in clinical responses to the anticancer agent 5-FU, and various reports have clearly demonstrated that DPD activity is closely correlated to mRNA levels. However, the regulatory mechanisms of DPD gene (DPYD) expression remain unclear. In this study, the regulatory mechanisms have been intensively studied.
INTRODUCTION
The antimetabolite 5-fluorouracil (5-FU) is one of the key agents in treatment of a large spectrum of cancers. Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in the degradation of 5-FU, and Ͼ80% of the administered dose of the pyrimidine analog is inactivated via this enzymemediated catabolic pathway; DPD is also known to be a principal factor in 5-FU pharmacokinetics, clinical toxicity, and drug resistance (1) (2) (3) (4) (5) . The enzyme demonstrates considerable variation (8-to 21-fold) in both healthy and cancer populations: 3% to 5% of individuals have reduced DPD activity, which is associated with severe and sometimes life-threatening 5-FU toxicity in cancer patients (6) . Because 5-FU accumulated in cancer cells is also rapidly converted into inactivated metabolites through catabolic pathways mediated by DPD, high DPD activity in cancer cells is an important determinant of 5-FU response (7) . This significant role of DPD in clinical 5-FU response has stimulated research aimed at prior laboratory prediction of individual response to 5-FU using DPD as a marker. The discovery that DPD deficiency is a pharmacogenetic disorder promoted the discovery of DPD gene (DPYD) mutations that are closely linked to DPD toxicity: To date, Ͼ20 polymorphisms of DPYD have been reported (8, 9) . Among these polymorphisms, the exon 14-skipping mutation (DPYD*2) appears to be the most prominent genetic change related to severe DPD deficiency (7) . However, it is now increasingly recognized that these variant alleles are insufficient in themselves to explain either polymorphic DPD activity in vivo or the majority (Ͼ85%) of cases of reduced DPD activity in cancer patients with 5-FU toxicity (5, 7, 10) .
Because various reports have clearly demonstrated that DPD activity closely correlates to mRNA levels, recent attention has been focused on the regulatory mechanisms of DPYD expression (10) . Nevertheless, unlike the well-characterized expression profiles of DPYD in cancer cells, the regulatory mechanisms of DPYD expression remain unclear, and even for the sequence of the 5Ј region, details are still controversial (8, 11) . In this study, we subcloned an approximately 3.0-kb [nucleotide (nt) Ϫ2918 to ϩ83] fragment of the 5Ј region of DPYD from a human placenta genome library. We then studied the regulatory mechanisms, focusing on the distinctive GC-rich sequence, and we found that aberrant methylation of the DPYD promotor region could influence cellular response to 5-FU through regulation of DPYD expression.
MATERIALS AND METHODS
Chemicals. 5-FU was generously provided by Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Japan). All other chemicals were of analytical grade and were purchased from Wako Pure Chemicals (Osaka, Japan) and Sigma (St. Louis, MO).
Cell Lines and RNA Preparation. Human cancer cell lines used were as follows: oral epidermoid carcinoma line KB (Dr. S. Akiyama; Kagoshima University, Kagoshima, Japan); colon adenocarcinoma cell line COLO201; oral squamous cell carcinoma lines HSC2, HSC3, HSC4, and Ca9-22; and hepatoma cell line HepG2 (The Japanese Cancer Research Resource Bank, Tokyo, Japan). Cell lines were maintained in RPMI 1640 or Dulbecco's modified Eagle's medium (Sigma-Aldrich Japan, Tokyo, Japan) supplemented with 10% fetal bovine serum (BioWhittaker, Verviers, Belgium) plus penicillin (50 IU/mL) and streptomycin (50 g/mL) with passage every 3 days. Total RNA was prepared from frozen cell pellets by using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions.
Reverse Transcription-Polymerase Chain Reaction. First-strand cDNA was synthesized from 2 g of total RNA with the use of random primer pd(N) 6 and avian myeloblastosis virus reverse transcriptase XL (Takara Bio Inc., Shiga, Japan). Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed using the TaqMan system on ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Primers and probe sequences used were as follows: DPYD1114F (forward primer, 5Ј-GCTGTCCCTGAGGAGATGGA-3Ј), DPYD1232R (reverse primer, 5Ј-TTGCTATGCAGTTTGTTCGGACA-3Ј), and probe (5Ј-6-carboxyl-fluorescein-TTCTGCCATTCCT-GTCCCCACG-N,N,NЈ,NЈ,-tetramethyl-6-carboxyrhodamine-3Ј). Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ␤-actin predeveloped TaqMan assay reagents were used as internal controls. Reactions were carried out under the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 60 cycles at 95°C for 15 seconds and 60°C for 1 minute. Subsequently, the cycle number at which the amount of amplified target crossed a fixed threshold (Ct) was determined. Three independent measurements were averaged, and relative gene expression levels were calculated as a ratio to the GAPDH or ACTB expression of each cell line.
Reporter Plasmid Construction. The 3.0-kb DNA fragment (nt Ϫ2918 to ϩ83) including the 5Ј region and the noncoding exon 1 of the DPYD gene was subcloned from a human placenta genome library. The HindIII and XhoI fragment was subcloned into MluI and XhoI sites of luciferase reporter plasmid pGL3-Basic (Promega, Madison, WI), which encodes firefly luciferase as a reporter, and this construct was designated pGL3-DPYDPro3.0. pGL3-DPYDPro0.34, which contained the region from nt Ϫ338 to ϩ83, was constructed by polymerase chain reaction (PCR) with pGL3-DPYDPro3.0 as a template. These constructs were found free of any genetic change by sequence analysis using RVprimer3, GLprimer2 (Promega), and several internal primers with Big Dye Terminators and ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Luciferase Reporter Assay. Transient transfection was performed as follows: pGL3-DPYDPro3.0 (0.5 g/15-mm well) and Renilla luciferase vector (pRL-TK; 0.01 g/15-mm well; Promega) as an internal control were mixed with 1.0 L of FuGENE 6 transfection reagent (Roche Diagnostic Co., Indianapolis, IN). Cells were incubated for 36 hours before analysis of luciferase reporter activity. The luciferase luminescence was measured by a single-sample luminometer, the Mini Lumat LB 9505 luminometer (Berthold Technolgies GmbH & Co KG, Bad Wildbad, Germany) using the Dual Luciferase Assay Kit (Promega). DPYD promoter activity in each cell line was calculated (as fold) relative to the activity in COLO201.
Bisulfite Sequencing. Genomic DNA was isolated from each cell line using the QIAamp DNA mini kit (Qiagen). One microgram of genomic DNA was treated with sodium bisulfite at 55°C for 12 hours and purified using QIAquick Spin columns (Qiagen). The Ϫ97 to ϩ63 fragment of the DPYD gene was amplified by hot-start PCR with these primers: DPYDProF9 (forward primer, 5Ј-GGGAGTCGTAGGATCGAGAGCGTA-GTTTCG-3Ј) and DPYDProE1R9 (reverse primer, 5Ј-GGTT-GGAGTTTGAGGACGTAAGGAGGGTTT-3Ј). The PCR comprised 40 cycles at an annealing temperature of 62°C with the bisulfite-treated DNA as templates. The purified PCR fragments were subcloned into pGEM-T Easy vector (Promega), and 10 clones of each product were sequenced using T7 primer.
5-Azacytidine Treatment. Cells were exposed to various concentrations of 5-azacytidine (0, 0.25, or 2.5 mol/L) and harvested on days 0, 5, 10, and 20 after the beginning of the treatments. 5-Azacytidine was added to culture medium every 3 days. For analysis of DPYD expression, cells were immediately frozen as pellets. For 5-FU cytotoxic assay, cells were collected by trypsinization and subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after treatment for 0, 5, and 15 days.
In vitro Methylated Promoter Reporter. In vitro methylation was performed essentially as described previously (12) . Briefly, pGL3-DPYDPro0.34 was digested with KpnI and XhoI, and the DPYDPro0.34 fragment was purified using the QIAquick Gel Extraction Kit (Qiagen). The purified fragment was separated into two tubes and reacted with or without 20 units of SssI methylase (New England BioLab Inc., Beverley, MA) at 37°C for 1 hour in a mixture (160 mmol/L S-adenosylmethionine and 1ϫ NEBuffer 2 containing 10 mmol/L Tris-HCl, 10 mmol/L MgCl 2 , 50 mmol/L NaCl 2 , and 1 mmol/L dithiothreitol). The methylation reaction was optimized by confirming methylation status using bisulfite sequencing. Fragments were purified by the phenol-chloroform method and precipitated with ethanol. Purified fragments were dissolved in H 2 O and ligated into KpnI-and XhoI-digested pGL3 basic vector at 16°C for 2 hours. Ligated reporter constructs were purified again as described above and dissolved in 10 mmol/L Tris (pH 8)-1 mmol/L EDTA buffer. Each DNA concentration was measured, and 0.2 or 0.4 g of reporter with control pRL-TK was finally subjected to transfection assays as described under Luciferase Reporter Assay.
Cytotoxic Assay. Drug-induced cytotoxicity was evaluated by conventional MTT dye reduction assay. Briefly, 4 ϫ 10 cells were seeded in each well of 96-microwell plates (Nunclon; Nunc, Roskilde, Denmark) with regular medium. After a 24-hour incubation, the medium was replaced, and cells were exposed to various concentrations of 5-FU for 72 hours. Then, 10 L of 0.4% MTT reagent and 0.1 mol/L sodium succinate were added to each well. After a 2-hour incubation, 150 L of dimethyl sulfoxide were added to dissolve the purple formazan precipitate. The formazan dye was measured spectrophotometrically (570 -650 nm) using MAXline microplate reader (Molecular Devices Corp., Sunnyvale, CA). The cytotoxic effect of Exogenous promoter activity of DPYD was measured by transient transfection assay of the 5Ј region of DPYD with the luciferase reporter gene. Luciferase activity normalized with pRL-TK in each cell line is expressed relative to the level in COLO201. Each group of data represents the mean Ϯ SD for three independent experiments. B and C, correlation analyses between endogenous gene expression levels and exogenous promoter activities of the cell lines, including (B) and excluding HSC3 and HepG2 (C). Univariate analyses were carried out with StatView J4.11 software (Abacus Co., Berkeley, CA). each treatment was assessed by the IC 50 value (inhibitory drug concentration of 50% cell growth:drug concentration of 50% absorbance of control).
RESULTS
Molecular Cloning of the 5 Region of the DPYD Gene. Shestopal et al. (11) (Fig. 1) . The sequence analysis revealed that our clone contained a region consistent with the sequence reported by Shestopal et al. (ref. 11 ; from nt Ϫ1152 to ϩ83), along with a novel upstream region as well (GenBank accession no. AB162145). As reported previously, the clone lacked a typical TATA or CCAAT box (11) , and, interestingly, we found 60 CpG sites located close to the transcriptional start site in the clone.
Endogenous and Exogenous Promoter Activity of DPYD in Cancer Cell Lines. The promoter activity of the cloned DPYD was evaluated in seven human cancer cell lines using luciferase reporter analysis. Transient transfection of luciferase reporter plasmid driven by the 5Ј region of DPYD demonstrated significantly different promoter activities among cell lines: activities were 6.6, 2.6, and 2.3 times stronger in HepG2, HSC2, and HSC3, respectively, than in COLO201, suggesting that promoter activity of DPYD could confer potential for DPYD gene expression (Fig. 2A) . The endogenous DPYD expressions analyzed using real-time RT-PCR showed that DPYD expression also varied among cell lines, i.e., it was more than 20 times higher in HSC2 than COLO201, but undetectable in HSC3 and HepG2. Although the relative gene expression levels did not correlate with the relative exogenous promoter activities in all cell lines (Fig. 2B ), they were largely correlative when HSC3 and HepG2 were excluded (r 2 ϭ 0.63; P ϭ 0.11; Fig. 2C ). In HSC3 and HepG2, there was a remarkable difference between exogenous promoter activity and expression level, indicating that some factors were interfering in the regulatory mechanism. The factors responsible for this discrepancy would likely be important factors of the transcription, so we focused on the identification of these factors. One of the likely mechanisms involved in the discrepancy is a genetic mutation in the promoter region, but no differences were detected in the sequence of the 5Ј region of DPYD.
Demethylation by 5-Azacytidine Treatment and Expression of DPYD. Findings in the sequence analysis showing that a total of 60 CpG sites existed in the region and that most of them were located close to the transcriptional start site led us to hypothesize that epigenetic alteration in the promoter region, i.e., aberrant methylation, might play an important role in the mechanisms of transcriptional regulation. To determine whether promoter methylation was actually participating in the transcriptional repression of DPYD in cancer cells, we performed reversal analysis of DNA methylation with 5-azacytidine treatment in HepG2. The cells were treated with vehicle, 0.25 or 2.5 mol/L 5-azacytidine, for 0, 5, 10, and 20 days (13) . Total RNAs were prepared from HepG2 cells in each condition, and real-time RT-PCR was performed with specific primer and probe sets for DPYD or GAPDH to clarify the influence of hypermethylation on DPYD mRNA levels. As expected, expression of DPYD was restored with 5-azacytidine treatment in a dose-and timedependent manner, although expression of GAPDH did not change (Fig. 3A) . We further analyzed expression levels of DPYD with or without 2.5 mol/L 5-azacytidine treatment for 15 days in cells with undetectable (HSC3 and HepG2) and with low (COLO201) and high (HSC2) levels of DPYD: The analysis demonstrated that 5-azacytidine treatment increased DPYD expression up to 27.4 and 4.5 times in HepG2 and HSC3 but decreased it in COLO201 and HSC2 (Fig. 3B) . The reverse of abnormal hypermethylation caused a remarkable increase of DPYD expression only in cells that showed extremely low (undetectable) DPYD expression; these cells, however, had potentially strong promoter activity, which led to a reduction in the initial discrepancy between expression level and promoter activity.
CpG Methylation Directly Suppressed DPYD Promoter Activity. To clarify the role of CpG methylation in DPYD promoter activity, we performed a luciferase reporter assay in HepG2 by transfection of in vitro methylated DPYD promoter. Methylated or unmethylated DPYD promoter was ligated into pGL3 basic and transiently transfected into HepG2 cells with pRL-TK as control. In this experiment, we used a deletion mutant of the DPYD promoter reporter (pGL3-DPYDPro0.34) because an efficient religation of the 0.34-bp fragment was thought to be better than the full-length DPYD promoter clone (DPYDPro3.0). Moreover, pGL3-DPYDPro0.34 showed strong promoter activity, greater than that of full-length pGL3-DPYDPro3.0 in HepG2 cells (data not shown). The methylated DPYD promoter clearly demonstrated a suppressive effect on promoter activity in HepG2 cells: The promoter activity was reduced. The reduction was below 45% of the control cells that were transfected with unmethylated promoter (P Ͻ 0.0001; Fig. 4 ). Transfection of pRL-TK as the control did not have any effect on the results.
Demethylation by 5-Azacytidine Treatment and Cellular Sensitivity to 5-Fluorouracil. Because DPYD expression is well known to be closely correlated with DPD activity and thus with 5-FU activity against cancer cells (10), we examined cellular sensitivity to 5-FU by MTT assay with or without 5-azacytidine treatment for 15 days in HepG2. The observed IC 50 value in the control cells was 2.2 mol/L, whereas the IC 50 values in cells treated with 0.25 and 2.5 mol/L 5-azacytidine were 2.8 and 16.1 mol/L, respectively. HepG2 showed 1.25-fold (P Ͻ 0.03) and 7.2-fold (P Ͻ 0.003) decreases in sensitivity to 5-FU with 0.25 and 2.5 mol/L 5-azacytidine treatment, respectively (Fig. 5A) . We further examined cellular sensitivity to 5-FU in other cell lines with or without 2.5 mol/L 5-azacytidine treatment for 15 days. Demethylation caused a remarkable decrease in sensitivity to 5-FU, along with a concurrent increase of DPYD expression in HSC3, suggesting that aberrant promoter methylation affects the transcriptional repression of DPYD and thus decreases DPD-mediated 5-FU degradation in the cells.
Nevertheless, the effect of 5-azacytidine treatment on cellular sensitivity to 5-FU and DPYD expression (and thus the relationship between them) varied among cell lines. The demethylation in COLO201 increased sensitivity to 5-FU, which was associated with a decrease in DPYD expression, whereas it decreased the sensitivity of HSC2 to 5-FU, despite the decreased DPYD expression (Fig. 5B) . These results can be interpreted to mean that some peculiar mechanisms other than the DPDmediated one are apparently involved in 5-FU response in HSC2, whereas the 5-FU response mechanisms in HepG2, HSC3, and COLO201 are DPD dependent.
Methylation Status of the CpG Island in the Core Promoter Region of DPYD. To clarify this hypothesis, the methylation status of CpG sites was studied using bisulfite sequence After 36 hours of incubation, luciferase activity was evaluated and calculated as a ratio to that of pRL-TK (right panel). Each group of data represents the mean Ϯ SD for three independent experiments. P was calculated by Student's t test. analysis focusing on the core promoter region of DPYD, which is likely the most important in transcriptional regulation (12, 14, 15) . Sodium bisulfite is a mutagen that can specifically deaminate Ͼ96% of the cytosine residues in single-stranded DNA via formation of a 5,6-dihydrocytosine-6-sulfonate intermediate. We analyzed the sequence of DNAs extracted from a total of seven cell lines, and after sodium bisulfite treatment, the 160-bp amplicons were subcloned into pGEM-T Easy vector, and 10 clones of each product were sequenced using T7 primer. As expected, residual cytosines that were unchanged after bisulfite treatment (primarily methylated cytosines) were detected at various CpG sites around the transcription start site (Fig. 6) . The methylated CpG sites at Ϫ62, Ϫ34, ϩ1, ϩ6, and ϩ8 were detected in cells with relatively low (KB) or undetectable (HSC3 and HepG2) DPYD expression, but were not detected in the other cell lines that had relatively high DPYD expression such as HSC2, HSC4, and Ca9-22. Among these methylated sites, the site at ϩ8 was commonly detected in cell lines showing reduced DPYD expression, including HSC3 and HepG2 cells. However, we were unable to find any specific methylated sites in COLO201.
DISCUSSION
In this study, we looked at mechanisms that might be responsible for the expression levels of DPYD in cancer cells, and we demonstrated for the first time that DPYD promoter methylation caused DPYD repression along with an alteration of 5-FU sensitivity in cancer cells such as HSC3 and HepG2.
The relative endogenous expression levels of DPYD largely correlated with the relative exogenous promoter activities (luciferase reporter activities) in most of the cell lines tested, suggesting that transcription activities of trans-acting factors were probably critical in determining their expression levels (Fig. 7) . Even so, some cells showed a discrepancy between endogenous and exogenous promoter activities. The lack of genetic variation in the 5Ј region of DPYD and the existence of numerous CpG sites located close to the transcriptional start site, which was consistent with the 5Ј regulatory regions of housekeeping genes and numerous tissue-specific genes (16), suggested the hypothesis that promoter methylation might play a role in repression of DPYD and could be responsible for the discrepancy between endogenous and exogenous promoter activities (refs. 12, 13, and 15; Fig. 7 ). In fact, our demethylation studies, transfection experiments with in vitro methylated promoter, and bisulfite sequencing analyses revealed the existence and significant role of promoter methylation. Furthermore, we observed that reversal of hypermethylation caused a decrease in sensitivity to 5-FU in HepG2 and HSC3 cells, correlated with an increase in DPYD expression. Aberrant promoter methylation of DPYD appeared to be one of the important factors in DPDmediated 5-FU responses, through repression of DPYD.
Nevertheless, a comprehensive view of the mechanisms of DPYD transcriptional regulation is still undetermined. Although the participation of aberrant promoter methylation in these complicated mechanisms has been suggested, some of our data clearly indicated that further investigations are required. In contrast to the findings with HSC3 and HepG2, 5-azacytidine treatment increased sensitivity to 5-FU and decreased DPYD expression in COLO201 cells. Because aberrant methylation is generally understood to act on gene silencing, these results can be interpreted to mean that demethylation acts on the reversal of inhibition of transcription repressors in some cases (Fig. 7, right  pathway) . DPYD expression could be repressed by the mechanisms, which in turn could cause the increase in cellular sensitivity to 5-FU in COLO201 cells. However, the specific mechanism is unclear at present. Although bisulfite sequence analysis indicated that the methylation at ϩ8 is the most likely factor associated with repression of DPYD, it is clear that large-scale investigations of methylated CpG sites in the DPYD region are necessary before any conclusion can be reached. We also need Fig. 6 Methylated CpG sites in the DPYD promoter region. DNAs extracted from seven cell lines were treated with 3 mol/L sodium bisulfite for 12 hours. The 160-bp amplicons were subcloned into pGEM-T Easy vector, and 10 clones of each product were sequenced using T7 primer. The putative methylated CpG sites were then classified into three groups according to the number of residual cytosines detected in the 10 clones: 0 -2, Ⅺ; 3-7, 0; and 8 -10, f. The transcription start site is indicated by an arrow.
to clarify the functional significance of all of the methylated sites and to determine whether some DPD-independent 5-FU-resistant mechanism exists. DPD-mediated degradation is not always the main mechanism of 5-FU resistance, and this was clear in the case of HSC2 in our study: Treatment with 5-azacytidine did decrease DPYD expression, but at the same time, it decreased the sensitivity of HSC2 to 5-FU. Recent reports have shown that multiple genes in various types of cancer cells are heavily methylated: 5-aza-deoxycytidine treatment demethylated the hMLH1 promoter, restored its expression, and sensitized the colorectal cancer cells to 5-FU treatment (17, 18) .
A variety of studies in both in vitro and clinical settings have found a close correlation between DPYD expression and 5-FU resistance (19) . Micrometastatic cancer cells can be detected in blood samples, and the methylation-specific PCR method targeting numerous important methylated CpG sites could prove to be a useful tool in predicting clinical sensitivity to 5-FU by using such blood samples. Our results here show that DPD activity is controlled at the level of transcription and that, among various mechanisms, aberrant methylation in the DPYD promoter may have some role. This could lead to a more precise understanding of the molecular basis of 5-FU resistance and thereby contribute to the development of personalized medicine. Fig. 7 Hypothetical model of regulation of DPDrelated 5-FU response in cancer cells. DPYD is transcribed with trans-acting factors, depending on the balance between activators and repressors, and expression level of DPYD correlates with its protein level and activity affecting 5-FU sensitivity. Promoter methylation may repress DPYD transcription in both activation and repression dominant status. Thus, the methylation status of DPYD could be a reliable marker for 5-FU sensitivity.
